No significant eGFR difference was observed between the SGLT2 inhibitor group and control group in patients with CKD (WMD −0.78 ml/min per 1.73 m2, (95% CI [−2.52 to 0.97]), I2 = 65.0%, 5 studies with 1,574 patients). Here, SLC5A2 is linked to chronic kidney disease.